Oral Immunotherapy in Food Allergy: A Critical Pediatric Perspective

Creative Commons License

AKARSU A., Brindisi G., Fiocchi A., Zicari A. M., Arasi S.

FRONTIERS IN PEDIATRICS, vol.10, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 10
  • Publication Date: 2022
  • Doi Number: 10.3389/fped.2022.842196
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
  • Keywords: children, cow's milk allergy, desensitization, food allergy, egg allergy, oral immunotherapy, peanut allergy, sustained responsiveness, COWS MILK ALLERGY, QUALITY-OF-LIFE, DOUBLE-BLIND, TOLERANCE INDUCTION, EGG ALLERGY, SUSTAINED UNRESPONSIVENESS, HENS EGG, PEANUT ALLERGY, EOSINOPHILIC ESOPHAGITIS, CHILDREN
  • Hacettepe University Affiliated: Yes


There is evidence that in children with persistent IgE-mediated food allergy (FA) to cow's milk, hen's egg, and peanut, oral allergen-specific immunotherapy (OIT) may increase the reaction threshold to the culprit food allergen(s). OIT may protect patients from the occurrence of severe reactions in case of accidental ingestion of the culprit food during treatment. Notwithstanding, many gaps are still unsolved, including safety issues, identification of predictive biomarkers, and post-desensitization efficacy. In this perspective, the use of omalizumab (Anti-IgE monoclonal antibody) has been proposed as an adjunctive treatment to OIT in order to reduce the risk of allergic reactions related to OIT. This review aims to summarize the current evidence and unmet needs on OIT in children with FA to enhance the development of longitudinal, prospective, and well-designed studies able to fill the current gaps soon.